Sign In
Buy AERI
$15.25
+0 (+0%)
At Close: Feb 17, 2023
Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates
06:19pm, Wednesday, 04'th Aug 2021
Aerie (AERI) delivered earnings and revenue surprises of -3.08% and 2.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Aerie Pharmaceuticals Announces Appointment of Leon J. Atencia, Director of Regulatory Affairs
06:30am, Thursday, 15'th Jul 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies f
Aerie Pharmaceuticals to Participate in the Raymond James Human Health Innovation Conference – UPDATED RELEASE
06:45am, Monday, 21'st Jun 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan
06:30am, Thursday, 17'th Jun 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
Aerie's (AERI) Q1 Loss Wider Than Expected, Revenues Miss
02:16pm, Thursday, 06'th May 2021
Aerie (AERI) incurs a wider loss in the first quarter of 2021 and sales miss expectations.
Aerie Pharmaceuticals, Inc. (AERI) CEO Vince Anido on Q1 2021 Results - Earnings Call Transcript
12:05am, Thursday, 06'th May 2021
Aerie Pharmaceuticals, Inc. (AERI) CEO Vince Anido on Q1 2021 Results - Earnings Call Transcript
Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Misses Revenue Estimates
07:10pm, Wednesday, 05'th May 2021
Aerie (AERI) delivered earnings and revenue surprises of -4.35% and -1.64%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Aerie (AERI) This Earnings Season?
10:32am, Tuesday, 04'th May 2021
Aerie (AERI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
01:47pm, Wednesday, 28'th Apr 2021
Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
06:30am, Wednesday, 28'th Apr 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
07:30am, Wednesday, 07'th Apr 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
Aerie (AERI) Up 11.8% Since Last Earnings Report: Can It Continue?
12:41pm, Saturday, 27'th Mar 2021
Aerie (AERI) reported earnings 30 days ago. What's next for the stock?
